Violet Therapeutics

CAMBRIDGE, MA · Founded 2021 · Biotech · Private

EphB3 inhibitor molecules for treating neurodegenerative diseases

Claim this profile

Follows are private to you and power your alerts

Updated · violettx.com

Sector
Biotech
Headquarters
CAMBRIDGE, MA
Founded
2021
Latest Form D
$7.4M, May 2023
Total capital
$7.4M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$7.4M
1 Form D · last May 2023
42 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
4 pending

Capital timeline

2023FEDERAL ↑EQUITY ↓Cumulative $7.4M1st Form D$7.4M
2023FEDERAL ↑EQUITY ↓Cumulative $7.4M1st Form D$7.4M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$7.4M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Atsushi UsamiDirectorNamed in SEC Form D filings
  • Jonathan BehrDirectorNamed in SEC Form D filings
  • Meredith FisherExecutive Officer, DirectorNamed in SEC Form D filings
  • William E YelleExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 4
  • PendingImidazopyridine Derivatives And Methods Of UseUSPTOApplication PCTUS2025015908
  • PendingImidazopyridine Derivatives And Methods Of UseUSPTOApplication PCTUS2025016140
  • PendingImidazopyridine Derivatives And Methods Of UseUSPTOApplication 63554892
Show all 4 patent records
  • Imidazopyridine Derivatives And Methods Of UseApplication PCTUS2025015908Pending
  • Imidazopyridine Derivatives And Methods Of UseApplication PCTUS2025016140Pending
  • Imidazopyridine Derivatives And Methods Of UseApplication 63554892Pending
  • Imidazopyridine Derivatives And Methods Of UseApplication 63554888Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .